MedTrace Logo

A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)

NCT05624281 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-01-12

No results posted yet for this study

Summary

This Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment and for whom no satisfactory authorized alternative therapy exists and who cannot participate in the ongoing 1199-0378 trial.

Conditions

  • Lung Diseases, Interstitial (in Pediatric Populations)
  • Childhood Interstitial Lung Disease (chILD)

Interventions

DRUG

nintedanib

nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents

Sponsors & Collaborators

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05624281 on ClinicalTrials.gov